A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer
Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femo...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Takehiko Nakasato [verfasserIn] Tatsuki Inoue [verfasserIn] Ryosuke Kato [verfasserIn] Yoshihiro Nakagami [verfasserIn] Kazuhiko Oshinomi [verfasserIn] Yoshiko Maeda [verfasserIn] Jun Morita [verfasserIn] Takeshi Shichijo [verfasserIn] Toshiko Yamochi [verfasserIn] Takashi Fukagai [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: IJU Case Reports - Wiley, 2019, 5(2022), 2, Seite 92-94 |
|---|---|
| Übergeordnetes Werk: |
volume:5 ; year:2022 ; number:2 ; pages:92-94 |
| Links: |
|---|
| DOI / URN: |
10.1002/iju5.12402 |
|---|
| Katalog-ID: |
DOAJ018354750 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ018354750 | ||
| 003 | DE-627 | ||
| 005 | 20230310095841.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/iju5.12402 |2 doi | |
| 035 | |a (DE-627)DOAJ018354750 | ||
| 035 | |a (DE-599)DOAJ85e71c5ebec741f7a03029cf189da243 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC870-923 | |
| 100 | 0 | |a Takehiko Nakasato |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression. | ||
| 650 | 4 | |a bladder cancer | |
| 650 | 4 | |a complete response | |
| 650 | 4 | |a metastasectomy | |
| 650 | 4 | |a pembrolizumab | |
| 650 | 4 | |a urothelial cancer | |
| 653 | 0 | |a Diseases of the genitourinary system. Urology | |
| 700 | 0 | |a Tatsuki Inoue |e verfasserin |4 aut | |
| 700 | 0 | |a Ryosuke Kato |e verfasserin |4 aut | |
| 700 | 0 | |a Yoshihiro Nakagami |e verfasserin |4 aut | |
| 700 | 0 | |a Kazuhiko Oshinomi |e verfasserin |4 aut | |
| 700 | 0 | |a Yoshiko Maeda |e verfasserin |4 aut | |
| 700 | 0 | |a Jun Morita |e verfasserin |4 aut | |
| 700 | 0 | |a Takeshi Shichijo |e verfasserin |4 aut | |
| 700 | 0 | |a Toshiko Yamochi |e verfasserin |4 aut | |
| 700 | 0 | |a Takashi Fukagai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t IJU Case Reports |d Wiley, 2019 |g 5(2022), 2, Seite 92-94 |w (DE-627)1760640581 |w (DE-600)3072753-4 |x 2577171X |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2022 |g number:2 |g pages:92-94 |
| 856 | 4 | 0 | |u https://doi.org/10.1002/iju5.12402 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/85e71c5ebec741f7a03029cf189da243 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1002/iju5.12402 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2577-171X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2022 |e 2 |h 92-94 | ||
| author_variant |
t n tn t i ti r k rk y n yn k o ko y m ym j m jm t s ts t y ty t f tf |
|---|---|
| matchkey_str |
article:2577171X:2022----::csocmltrsosfloighamnsrtoopmrlzmbnmtsaetmfrugn |
| hierarchy_sort_str |
2022 |
| callnumber-subject-code |
RC |
| publishDate |
2022 |
| allfields |
10.1002/iju5.12402 doi (DE-627)DOAJ018354750 (DE-599)DOAJ85e71c5ebec741f7a03029cf189da243 DE-627 ger DE-627 rakwb eng RC870-923 Takehiko Nakasato verfasserin aut A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression. bladder cancer complete response metastasectomy pembrolizumab urothelial cancer Diseases of the genitourinary system. Urology Tatsuki Inoue verfasserin aut Ryosuke Kato verfasserin aut Yoshihiro Nakagami verfasserin aut Kazuhiko Oshinomi verfasserin aut Yoshiko Maeda verfasserin aut Jun Morita verfasserin aut Takeshi Shichijo verfasserin aut Toshiko Yamochi verfasserin aut Takashi Fukagai verfasserin aut In IJU Case Reports Wiley, 2019 5(2022), 2, Seite 92-94 (DE-627)1760640581 (DE-600)3072753-4 2577171X nnns volume:5 year:2022 number:2 pages:92-94 https://doi.org/10.1002/iju5.12402 kostenfrei https://doaj.org/article/85e71c5ebec741f7a03029cf189da243 kostenfrei https://doi.org/10.1002/iju5.12402 kostenfrei https://doaj.org/toc/2577-171X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 5 2022 2 92-94 |
| spelling |
10.1002/iju5.12402 doi (DE-627)DOAJ018354750 (DE-599)DOAJ85e71c5ebec741f7a03029cf189da243 DE-627 ger DE-627 rakwb eng RC870-923 Takehiko Nakasato verfasserin aut A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression. bladder cancer complete response metastasectomy pembrolizumab urothelial cancer Diseases of the genitourinary system. Urology Tatsuki Inoue verfasserin aut Ryosuke Kato verfasserin aut Yoshihiro Nakagami verfasserin aut Kazuhiko Oshinomi verfasserin aut Yoshiko Maeda verfasserin aut Jun Morita verfasserin aut Takeshi Shichijo verfasserin aut Toshiko Yamochi verfasserin aut Takashi Fukagai verfasserin aut In IJU Case Reports Wiley, 2019 5(2022), 2, Seite 92-94 (DE-627)1760640581 (DE-600)3072753-4 2577171X nnns volume:5 year:2022 number:2 pages:92-94 https://doi.org/10.1002/iju5.12402 kostenfrei https://doaj.org/article/85e71c5ebec741f7a03029cf189da243 kostenfrei https://doi.org/10.1002/iju5.12402 kostenfrei https://doaj.org/toc/2577-171X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 5 2022 2 92-94 |
| allfields_unstemmed |
10.1002/iju5.12402 doi (DE-627)DOAJ018354750 (DE-599)DOAJ85e71c5ebec741f7a03029cf189da243 DE-627 ger DE-627 rakwb eng RC870-923 Takehiko Nakasato verfasserin aut A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression. bladder cancer complete response metastasectomy pembrolizumab urothelial cancer Diseases of the genitourinary system. Urology Tatsuki Inoue verfasserin aut Ryosuke Kato verfasserin aut Yoshihiro Nakagami verfasserin aut Kazuhiko Oshinomi verfasserin aut Yoshiko Maeda verfasserin aut Jun Morita verfasserin aut Takeshi Shichijo verfasserin aut Toshiko Yamochi verfasserin aut Takashi Fukagai verfasserin aut In IJU Case Reports Wiley, 2019 5(2022), 2, Seite 92-94 (DE-627)1760640581 (DE-600)3072753-4 2577171X nnns volume:5 year:2022 number:2 pages:92-94 https://doi.org/10.1002/iju5.12402 kostenfrei https://doaj.org/article/85e71c5ebec741f7a03029cf189da243 kostenfrei https://doi.org/10.1002/iju5.12402 kostenfrei https://doaj.org/toc/2577-171X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 5 2022 2 92-94 |
| allfieldsGer |
10.1002/iju5.12402 doi (DE-627)DOAJ018354750 (DE-599)DOAJ85e71c5ebec741f7a03029cf189da243 DE-627 ger DE-627 rakwb eng RC870-923 Takehiko Nakasato verfasserin aut A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression. bladder cancer complete response metastasectomy pembrolizumab urothelial cancer Diseases of the genitourinary system. Urology Tatsuki Inoue verfasserin aut Ryosuke Kato verfasserin aut Yoshihiro Nakagami verfasserin aut Kazuhiko Oshinomi verfasserin aut Yoshiko Maeda verfasserin aut Jun Morita verfasserin aut Takeshi Shichijo verfasserin aut Toshiko Yamochi verfasserin aut Takashi Fukagai verfasserin aut In IJU Case Reports Wiley, 2019 5(2022), 2, Seite 92-94 (DE-627)1760640581 (DE-600)3072753-4 2577171X nnns volume:5 year:2022 number:2 pages:92-94 https://doi.org/10.1002/iju5.12402 kostenfrei https://doaj.org/article/85e71c5ebec741f7a03029cf189da243 kostenfrei https://doi.org/10.1002/iju5.12402 kostenfrei https://doaj.org/toc/2577-171X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 5 2022 2 92-94 |
| allfieldsSound |
10.1002/iju5.12402 doi (DE-627)DOAJ018354750 (DE-599)DOAJ85e71c5ebec741f7a03029cf189da243 DE-627 ger DE-627 rakwb eng RC870-923 Takehiko Nakasato verfasserin aut A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression. bladder cancer complete response metastasectomy pembrolizumab urothelial cancer Diseases of the genitourinary system. Urology Tatsuki Inoue verfasserin aut Ryosuke Kato verfasserin aut Yoshihiro Nakagami verfasserin aut Kazuhiko Oshinomi verfasserin aut Yoshiko Maeda verfasserin aut Jun Morita verfasserin aut Takeshi Shichijo verfasserin aut Toshiko Yamochi verfasserin aut Takashi Fukagai verfasserin aut In IJU Case Reports Wiley, 2019 5(2022), 2, Seite 92-94 (DE-627)1760640581 (DE-600)3072753-4 2577171X nnns volume:5 year:2022 number:2 pages:92-94 https://doi.org/10.1002/iju5.12402 kostenfrei https://doaj.org/article/85e71c5ebec741f7a03029cf189da243 kostenfrei https://doi.org/10.1002/iju5.12402 kostenfrei https://doaj.org/toc/2577-171X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 5 2022 2 92-94 |
| language |
English |
| source |
In IJU Case Reports 5(2022), 2, Seite 92-94 volume:5 year:2022 number:2 pages:92-94 |
| sourceStr |
In IJU Case Reports 5(2022), 2, Seite 92-94 volume:5 year:2022 number:2 pages:92-94 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
bladder cancer complete response metastasectomy pembrolizumab urothelial cancer Diseases of the genitourinary system. Urology |
| isfreeaccess_bool |
true |
| container_title |
IJU Case Reports |
| authorswithroles_txt_mv |
Takehiko Nakasato @@aut@@ Tatsuki Inoue @@aut@@ Ryosuke Kato @@aut@@ Yoshihiro Nakagami @@aut@@ Kazuhiko Oshinomi @@aut@@ Yoshiko Maeda @@aut@@ Jun Morita @@aut@@ Takeshi Shichijo @@aut@@ Toshiko Yamochi @@aut@@ Takashi Fukagai @@aut@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
1760640581 |
| id |
DOAJ018354750 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ018354750</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310095841.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/iju5.12402</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ018354750</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ85e71c5ebec741f7a03029cf189da243</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Takehiko Nakasato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bladder cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">complete response</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metastasectomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pembrolizumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">urothelial cancer</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tatsuki Inoue</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ryosuke Kato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshihiro Nakagami</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kazuhiko Oshinomi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshiko Maeda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jun Morita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takeshi Shichijo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Toshiko Yamochi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takashi Fukagai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">IJU Case Reports</subfield><subfield code="d">Wiley, 2019</subfield><subfield code="g">5(2022), 2, Seite 92-94</subfield><subfield code="w">(DE-627)1760640581</subfield><subfield code="w">(DE-600)3072753-4</subfield><subfield code="x">2577171X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:92-94</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/iju5.12402</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/85e71c5ebec741f7a03029cf189da243</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/iju5.12402</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2577-171X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">92-94</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Takehiko Nakasato |
| spellingShingle |
Takehiko Nakasato misc RC870-923 misc bladder cancer misc complete response misc metastasectomy misc pembrolizumab misc urothelial cancer misc Diseases of the genitourinary system. Urology A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer |
| authorStr |
Takehiko Nakasato |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760640581 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC870-923 |
| illustrated |
Not Illustrated |
| issn |
2577171X |
| topic_title |
RC870-923 A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer bladder cancer complete response metastasectomy pembrolizumab urothelial cancer |
| topic |
misc RC870-923 misc bladder cancer misc complete response misc metastasectomy misc pembrolizumab misc urothelial cancer misc Diseases of the genitourinary system. Urology |
| topic_unstemmed |
misc RC870-923 misc bladder cancer misc complete response misc metastasectomy misc pembrolizumab misc urothelial cancer misc Diseases of the genitourinary system. Urology |
| topic_browse |
misc RC870-923 misc bladder cancer misc complete response misc metastasectomy misc pembrolizumab misc urothelial cancer misc Diseases of the genitourinary system. Urology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
IJU Case Reports |
| hierarchy_parent_id |
1760640581 |
| hierarchy_top_title |
IJU Case Reports |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760640581 (DE-600)3072753-4 |
| title |
A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer |
| ctrlnum |
(DE-627)DOAJ018354750 (DE-599)DOAJ85e71c5ebec741f7a03029cf189da243 |
| title_full |
A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer |
| author_sort |
Takehiko Nakasato |
| journal |
IJU Case Reports |
| journalStr |
IJU Case Reports |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
92 |
| author_browse |
Takehiko Nakasato Tatsuki Inoue Ryosuke Kato Yoshihiro Nakagami Kazuhiko Oshinomi Yoshiko Maeda Jun Morita Takeshi Shichijo Toshiko Yamochi Takashi Fukagai |
| container_volume |
5 |
| class |
RC870-923 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Takehiko Nakasato |
| doi_str_mv |
10.1002/iju5.12402 |
| author2-role |
verfasserin |
| title_sort |
case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer |
| callnumber |
RC870-923 |
| title_auth |
A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer |
| abstract |
Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression. |
| abstractGer |
Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression. |
| abstract_unstemmed |
Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
2 |
| title_short |
A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer |
| url |
https://doi.org/10.1002/iju5.12402 https://doaj.org/article/85e71c5ebec741f7a03029cf189da243 https://doaj.org/toc/2577-171X |
| remote_bool |
true |
| author2 |
Tatsuki Inoue Ryosuke Kato Yoshihiro Nakagami Kazuhiko Oshinomi Yoshiko Maeda Jun Morita Takeshi Shichijo Toshiko Yamochi Takashi Fukagai |
| author2Str |
Tatsuki Inoue Ryosuke Kato Yoshihiro Nakagami Kazuhiko Oshinomi Yoshiko Maeda Jun Morita Takeshi Shichijo Toshiko Yamochi Takashi Fukagai |
| ppnlink |
1760640581 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1002/iju5.12402 |
| callnumber-a |
RC870-923 |
| up_date |
2024-07-03T17:26:58.771Z |
| _version_ |
1803579680380420096 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ018354750</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310095841.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/iju5.12402</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ018354750</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ85e71c5ebec741f7a03029cf189da243</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Takehiko Nakasato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60‐year‐old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD‐L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow‐up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long‐term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD‐L1 expression.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bladder cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">complete response</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metastasectomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pembrolizumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">urothelial cancer</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tatsuki Inoue</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ryosuke Kato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshihiro Nakagami</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kazuhiko Oshinomi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshiko Maeda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jun Morita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takeshi Shichijo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Toshiko Yamochi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takashi Fukagai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">IJU Case Reports</subfield><subfield code="d">Wiley, 2019</subfield><subfield code="g">5(2022), 2, Seite 92-94</subfield><subfield code="w">(DE-627)1760640581</subfield><subfield code="w">(DE-600)3072753-4</subfield><subfield code="x">2577171X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:92-94</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/iju5.12402</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/85e71c5ebec741f7a03029cf189da243</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/iju5.12402</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2577-171X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">92-94</subfield></datafield></record></collection>
|
| score |
7.4019423 |